MarketLens

Log in

What Makes Akeso's ASCO 2026 Plenary Session So Crucial

1 months ago
SHARE THIS ON:

What Makes Akeso's ASCO 2026 Plenary Session So Crucial

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 months ago

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026

Akari Therapeutics highlighted its differentiated PH1 payload platform for KRAS-driven cancers following the 2026 ASCO conference. The company emphasized the evolving antibody-drug conjugate (ADC) lan...
Stock News1 months ago

ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential

Oricell Therapeutics' Ori-C101 achieved a 66.7% objective response rate (ORR) in patients with late-line hepatocellular carcinoma (HCC). These clinical results, presented at ASCO 2026, suggest potenti...
Stock News1 months ago

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

Akeso’s ivonescimab plus chemotherapy demonstrated a 34% reduction in the risk of death (HR=0.66) compared to PD-1 plus chemotherapy in first-line sq-NSCLC patients. These landmark HARMONi-6 results w...
Stock News1 months ago

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

Bicycle Therapeutics will present initial Phase 2 Duravelo-2 trial data for zelenectide pevedotin in metastatic urothelial cancer at the 2026 ASCO Annual Meeting. The study evaluates the drug's effica...

Breaking News

View All →

Top Headlines

View More →
Stock News28 minutes ago

Meta discontinues AI image feature days after launch

Stock News59 minutes ago

Missed Nvidia's Run? SMH Holders Made 113% Over 12 Months Anyway

Stock News1 hour ago

Apple Lawsuit Claims OpenAI is Developing AI Devices Using Stolen Tech

Stock News1 hour ago

Apple vs. Broadcom: Is Either Stock a Buy After Their $30 Billion Chip Partnership?

Stock News1 hour ago

Apple sues OpenAI, alleging artificial intelligence company stole trade secrets